{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:33:54Z","timestamp":1793144034710,"version":"4.5.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"73","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"crossref","award":["P3-00083"],"award-info":[{"award-number":["P3-00083"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Horizon 2020 Framework Program for Research and Innovation of the European Commission"},{"name":"RISCC Network","award":["847845"],"award-info":[{"award-number":["847845"]}]},{"name":"Horizon 2020 Framework Program for Research and Innovation of the European Commission"},{"name":"RISCC Network","award":["101079944"],"award-info":[{"award-number":["101079944"]}]},{"name":"European Joint Action EUCansScreen"},{"name":"European Initiative for Cervical Cancer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The substantial changes of human papillomavirus (HPV) type distribution and reductions of cervical precancer and cancer incidence in vaccinated populations, which are entering screening programs now, require reassessment of screening and triage approaches to maintain the balance of benefits and harms of cervical cancer screening. The reduction of precancer and cancer in vaccinated populations affects the risk indicated by most screening and triage tests. Among HPV-positive women, the type distribution changes in vaccinated women to less carcinogenic types that are less likely to progress to precancer, and that cause precancers that are less likely to invade. Conversely, HPV vaccines do not affect the natural history of existing HPV infections. Although infections with vaccine-targeted types are rare in vaccinated populations, their risk of precancer and cancer is not reduced. Host biomarkers that are more closely linked to the carcinogenic process are more likely to perform well in vaccinated individuals compared with biomarkers that mostly reflect HPV infections. We summarize data on HPV screening and triage tests, including cytology, dual stain, and methylation tests, either directly evaluated in vaccinated populations or in HPV genotype strata to estimate their performance in vaccinated populations. Combinations of limited or extended genotyping HPV tests with triage biomarkers can provide meaningful risk stratification for both unvaccinated and vaccinated populations.<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgag013","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:39:45Z","timestamp":1778153985000},"page":"164-172","source":"Crossref","is-referenced-by-count":2,"title":["How to evaluate and select cervical screening and triage tests in vaccinated populations"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1251-0836","authenticated-orcid":false,"given":"Nicolas","family":"Wentzensen","sequence":"first","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Arbyn","sequence":"additional","affiliation":[{"name":"Unit of Cancer Epidemiology, Belgian Cancer Centre , Sciensano, Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Poljak","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana , Ljubljana,","place":["Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026083104014879200_lgag013-B1","doi-asserted-by":"crossref","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","article-title":"Carcinogenic human papillomavirus infection","volume":"2","author":"Schiffman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2026083104014879200_lgag013-B2","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMsr2030640","article-title":"The IARC perspective on cervical cancer screening","volume":"385","author":"Bouvard","year":"2021","journal-title":"N Engl J Med"},{"key":"2026083104014879200_lgag013-B3","doi-asserted-by":"crossref","first-page":"e453-63","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis","volume":"4","author":"Bruni","year":"2016","journal-title":"Lancet Glob Health"},{"key":"2026083104014879200_lgag013-B4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ygyno.2025.03.008","article-title":"Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: a systematic review of population level data and modelling studies","volume":"195","author":"de Bondt","year":"2025","journal-title":"Gynecol Oncol"},{"key":"2026083104014879200_lgag013-B5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"2026083104014879200_lgag013-B6","doi-asserted-by":"crossref","first-page":"l1161","DOI":"10.1136\/bmj.l1161","article-title":"Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study","volume":"365","author":"Palmer","year":"2019","journal-title":"BMJ"},{"key":"2026083104014879200_lgag013-B7","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"2026083104014879200_lgag013-B8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jnci\/djae042","article-title":"Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer","volume":"116","author":"Arbyn","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026083104014879200_lgag013-B9","doi-asserted-by":"crossref","first-page":"e087326","DOI":"10.1136\/bmj-2025-087326","article-title":"Extended follow-up of invasive cervical cancer risk after quadrivalent HPV vaccination: nationwide, register based study","volume":"392","author":"Wu","year":"2026","journal-title":"BMJ"},{"key":"2026083104014879200_lgag013-B10","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S2468-2667(25)00301-9","article-title":"Benefits beyond measure: herd effects of HPV vaccines","volume":"11","author":"Wentzensen","year":"2026","journal-title":"Lancet Public Health"},{"key":"2026083104014879200_lgag013-B11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature","volume":"404","author":"Wei","year":"2024","journal-title":"Lancet"},{"key":"2026083104014879200_lgag013-B12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ygyno.2019.02.016","article-title":"HPV infections and cytologic abnormalities in vaccinated women 21-34\u202fyears of age: results from the baseline phase of the Onclarity trial","volume":"153","author":"Wright","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2026083104014879200_lgag013-B13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication","volume":"128","author":"Li","year":"2011","journal-title":"Int J Cancer"},{"key":"2026083104014879200_lgag013-B14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"2026083104014879200_lgag013-B15","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1016\/j.vaccine.2007.11.069","article-title":"Cervical cancer screening following prophylactic human papillomavirus vaccination","volume":"26 Suppl 1","author":"Franco","year":"2008","journal-title":"Vaccine."},{"key":"2026083104014879200_lgag013-B16","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1055-9965.EPI-17-0534","article-title":"Defining optimal triage strategies for hrHPV screen-positive women-an evaluation of HPV 16\/18 genotyping, cytology, and p16\/Ki-67 cytoimmunochemistry","volume":"26","author":"Stanczuk","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026083104014879200_lgag013-B17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1158\/2159-8290.CD-12-0196","article-title":"From differences in means between cases and controls to risk stratification: a business plan for biomarker development","volume":"3","author":"Wentzensen","year":"2013","journal-title":"Cancer Discov"},{"key":"2026083104014879200_lgag013-B18","doi-asserted-by":"crossref","first-page":"e068582","DOI":"10.1136\/bmj-2021-068582","article-title":"National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study","volume":"376","author":"Smith","year":"2022","journal-title":"BMJ"},{"key":"2026083104014879200_lgag013-B19","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/jnci\/djac107","article-title":"Performance of cervical screening a decade following HPV vaccination: the Costa Rica vaccine trial","volume":"114","author":"Hu","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2026083104014879200_lgag013-B20","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw216","article-title":"Optimal cervical cancer screening in women vaccinated against human papillomavirus","volume":"109","author":"Kim","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2026083104014879200_lgag013-B21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.7326\/ANNALS-25-03192","article-title":"Optimizing cervical cancer screening by age at vaccination for human papillomavirus: health and resource implications","volume":"179","author":"Pedersen","year":"2026","journal-title":"Ann Intern Med"},{"key":"2026083104014879200_lgag013-B22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.7326\/ANNALS-25-05559","article-title":"Adapting cervical cancer screening in vaccinated populations: individualized versus population-based approaches","volume":"179","author":"Wentzensen","year":"2026","journal-title":"Ann Intern Med"},{"key":"2026083104014879200_lgag013-B23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ijc.31094","article-title":"What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study","volume":"142","author":"Landy","year":"2018","journal-title":"Int J Cancer"},{"key":"2026083104014879200_lgag013-B24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1470-2045(18)30836-2","article-title":"Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study","volume":"20","author":"Simms","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026083104014879200_lgag013-B25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ygyno.2018.12.019","article-title":"Pathways to a cancer-free future: a protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia","volume":"152","author":"Velentzis","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2026083104014879200_lgag013-B26","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/ijc.70119","article-title":"Epidemiological approaches to evaluate clinical unmasking of HPV-associated cervical lesions in the HPV vaccination era","volume":"158","author":"Tota","year":"2026","journal-title":"Int J Cancer"},{"key":"2026083104014879200_lgag013-B27","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jcv.2015.11.015","article-title":"Triage of HPV positive women in cervical cancer screening","volume":"76","author":"Wentzensen","year":"2016","journal-title":"J Clin Virol"},{"key":"2026083104014879200_lgag013-B28","doi-asserted-by":"crossref","first-page":"e29881","DOI":"10.1002\/jmv.29881","article-title":"Criteria for second generation comparator tests in validation of novel HPV DNA tests for use in cervical cancer screening","volume":"96","author":"Arbyn","year":"2024","journal-title":"J Med Virol"},{"key":"2026083104014879200_lgag013-B29","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.cmi.2021.04.031","article-title":"2020 list of human papillomavirus assays suitable for primary cervical cancer screening","volume":"27","author":"Arbyn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026083104014879200_lgag013-B30","doi-asserted-by":"crossref","first-page":"105671","DOI":"10.1016\/j.jcv.2024.105671","article-title":"2023 global inventory of commercial molecular tests for human papillomaviruses (HPV)","volume":"172","author":"Poljak","year":"2024","journal-title":"J Clin Virol"},{"key":"2026083104014879200_lgag013-B31","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J Infect Dis"},{"key":"2026083104014879200_lgag013-B32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/LGT.0000000000000865","article-title":"Applying results of extended genotyping to management of positive cervicovaginal human papillomavirus test results: enduring guidelines","volume":"29","author":"Massad","year":"2025","journal-title":"J Low Genit Tract Dis"},{"key":"2026083104014879200_lgag013-B33","author":"Australian Government Depatrment of Health, Disability and Aging","year":"2026"},{"key":"2026083104014879200_lgag013-B34","author":"Sweden","year":"2026"},{"key":"2026083104014879200_lgag013-B35","first-page":"CD009069","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026083104014879200_lgag013-B36","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/jnci\/djae283","article-title":"Impact of knowledge of human papillomavirus positivity on cervical cytology performance in Latin America","volume":"117","author":"Ram\u00edrez","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"2026083104014879200_lgag013-B37","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/cncy.22572","article-title":"Cytology interpretation after a change to HPV testing in primary cervical screening: observational study from the English pilot","volume":"130","author":"Rebolj","year":"2022","journal-title":"Cancer Cytopathol"},{"key":"2026083104014879200_lgag013-B38","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamainternmed.2019.0306","article-title":"Clinical evaluation of human papillomavirus screening with p16\/Ki-67 dual stain triage in a large organized cervical cancer screening program","volume":"179","author":"Wentzensen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2026083104014879200_lgag013-B39","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO-25-00689","article-title":"Long-term prospective cohort study of cervical cancer screening using triage of women who are human papillomavirus-positive with dual stain and human papillomavirus genotyping","volume":"44","author":"Wentzensen","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026083104014879200_lgag013-B40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/ijc.33812","article-title":"Clinical validation of p16\/Ki-67 dual-stained cytology triage of HPV-positive women: results from the IMPACT trial","volume":"150","author":"Wright","year":"2022","journal-title":"Int J Cancer"},{"key":"2026083104014879200_lgag013-B41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jasc.2024.09.003","article-title":"Triage options for positive high-risk HPV results from HPV-based cervical cancer screening: a review of the potential alternatives to Papanicolaou test cytology","volume":"14","author":"Thrall","year":"2025","journal-title":"J Am Soc Cytopathol"},{"key":"2026083104014879200_lgag013-B42","doi-asserted-by":"crossref","first-page":"105149","DOI":"10.1016\/j.ebiom.2024.105149","article-title":"Comparison of HPV-positive triage strategies combining extended genotyping with cytology or p16\/ki67 dual staining in the Italian NTCC2 study","volume":"104","author":"Benevolo","year":"2024","journal-title":"EBioMed"},{"key":"2026083104014879200_lgag013-B43","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.3390\/ijms24087158","article-title":"Triaging HPV-positive cervical samples with p16 and Ki-67 dual stained cytology within an organized screening program: a prospective observational study from western Norway","volume":"24","author":"\u00d8vestad","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026083104014879200_lgag013-B44","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/ijc.28900","article-title":"The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments","volume":"136","author":"Bergeron","year":"2015","journal-title":"Int J Cancer"},{"key":"2026083104014879200_lgag013-B45","doi-asserted-by":"crossref","first-page":"e1002388","DOI":"10.1371\/journal.pmed.1002388","article-title":"Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial","volume":"14","author":"Canfell","year":"2017","journal-title":"PLoS Med"},{"key":"2026083104014879200_lgag013-B46","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1158\/1055-9965.EPI-12-0905","article-title":"Human papillomavirus DNA methylation as a potential biomarker for cervical cancer","volume":"21","author":"Clarke","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026083104014879200_lgag013-B47","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/ijc.27750","article-title":"Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia","volume":"132","author":"Mirabello","year":"2013","journal-title":"Int J Cancer"},{"key":"2026083104014879200_lgag013-B48","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/jnci\/djs425","article-title":"Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3","volume":"104","author":"Wentzensen","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2026083104014879200_lgag013-B49","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-17-3251","article-title":"Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women","volume":"24","author":"Clarke","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026083104014879200_lgag013-B50","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.3390\/ijms24076479","article-title":"The role of methylation of host and\/or human papillomavirus (HPV) DNA in management of cervical intraepithelial neoplasia grade 2 (CIN2) lesions","volume":"24","author":"Dovnik","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026083104014879200_lgag013-B51","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/15592294.2018.1507197","article-title":"Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer","volume":"13","author":"Verlaat","year":"2018","journal-title":"Epigenetics"},{"key":"2026083104014879200_lgag013-B52","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/ijc.35044","article-title":"Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesions","volume":"155","author":"Louvanto","year":"2024","journal-title":"Int J Cancer"},{"key":"2026083104014879200_lgag013-B53","doi-asserted-by":"crossref","first-page":"e70022","DOI":"10.1002\/cncy.70022","article-title":"Assessment of the efficacy and accuracy of cervical cytology screening with the hologic genius digital diagnostics system","volume":"133","author":"Elishaev","year":"2025","journal-title":"Cancer Cytopathol"},{"key":"2026083104014879200_lgag013-B54","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/jnci\/djaa066","article-title":"Accuracy and efficiency of deep-learning-based automation of dual stain cytology in cervical cancer screening","volume":"113","author":"Wentzensen","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026083104014879200_lgag013-B55","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/LGT.0000000000000802","article-title":"Recommendations for use of p16\/Ki67 dual stain for management of individuals testing positive for human papillomavirus","volume":"28","author":"Clarke","year":"2024","journal-title":"J Low Genit Tract Dis"},{"key":"2026083104014879200_lgag013-B56","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virol.2013.07.015","article-title":"A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types","volume":"445","author":"Bzhalava","year":"2013","journal-title":"Virology"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2026\/73\/164\/70870260\/lgag013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2026\/73\/164\/70870260\/lgag013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:01:59Z","timestamp":1788163319000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2026\/73\/164\/8776089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":56,"journal-issue":{"issue":"73","published-online":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgag013","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8,1]]}}}